Clinical Trial Update: Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years

View source ↗

Summary

This update describes long-term outcomes of disseminated HER2-positive breast cancer patients treated with trastuzumab who achieved complete response, partial r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Asociación para el Progreso de la Oncología en Málaga | Conditions: HER-2 Positive Breast Cancer | Status: COMPLETED